Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 1, 2012, Pages 65-79

  Akanbi, Maxwell O ^a   Scarci, Kimberly ^b   Taiwo, Babafemi ^c   Murphy, Robert L ^c  

^a UNIVERSITY OF JOS   (Nigeria)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antiretroviral therapy; HIV; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitor

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANEMIA; ANTIVIRAL THERAPY; BONE DENSITY; BONE MARROW SUPPRESSION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERPIGMENTATION; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; PANCREATITIS; PERIPHERAL NEUROPATHY; RASH; REVIEW; SIDE EFFECT;

ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; NUCLEOSIDES; NUCLEOTIDES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 83455201429     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.642865     Document Type: Review

References (133)

1. Sterne JAC, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005;366:378-84
2. Gazzard BG, on behalf of the BTGWG. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008;9:563-608
3. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral Treatment of Adult HIV Infection. JAMA 2008;300:555-70
4. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach: 2010 revision. World Health Organization; Geneva: 2010
5. Piliero PJ. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2004;37(Suppl 1):S2-S12
6. Beach JW. Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin Ther 1998;20:2-25; discussion 1
7. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65:65-70
8. Garvey L, Winston A, Walsh J, et al. Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Neurology 2011;76:693-700
9. Smurzynski M, Wu K, Letendre S, et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011;25:357-65
10. ZERIT (package insert). Bristol-Myers Squibb Co. Princeton NJ 08543 USA: GlaxoSmithKline; 2009. Available from: http://wwwomsjorg/drugs/ZERITpdf.
11. Levine AM, Wernz JC, Kaplan L, et al. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial. JAMA 1991;266:84-8
12. Rausch DM, Heyes MP, Murray EA, Eiden LE. Zidovudine treatment prolongs survival and decreases virus load in the central nervous system of rhesus macaques infected perinatally with simian immunodeficiency virus. J Infect Dis 1995;172:59-69
13. Chappuy H, Treluyer JM, Jullien V, et al. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004;48:4332-6
14. Bonora S, Requena DD, Chiesa E, et al. Transplacental passage of tenofovir and other antiretrovirals at delivery [abstract #738a]. In: Fourteenth Conference on Retroviruses and Opportunistic Infections; Los Angeles: 2007
15. Dudley MN. Clinical pharmacokinetics of nucleoside antiretroviral agents. J Infect Dis 1995;171(Suppl 2):S99-112
16. Amantea MA. Should the dosage of zidovudine be adjusted in HIV-infected patients with impaired renal function? Am J Hosp Pharm 1990;47:618-19
17. Kimmel PL, Lew SQ, Umana WO, et al. Pharmacokinetics of zidovudine in HIV-infected patients with end-stage renal disease. Blood Purif 1995;13:340-6
18. Videx (package insert). Bristol-Myers Squibb Co. Princeton, NJ 08543 USA. Available from: http:// wwwpackageinsertsbmscom/pi/ pi-videx-ecpdf
19. Knupp CA, Shyu WC, Dolin R, et al. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther 1991;49:523-35
20. Hoetelmans RM, van Heeswijk RP, Profijt M, et al. Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals. AIDS 1998;12:F211-16
21. Zhou L, Kaul S, Liu-Kreyche P, et al. Disposition of [1′-14C] Stavudine after oral administration to humans. Drug Metab Dispos 2010;38:655-66
22. Becher F, Landman R, Mboup S, et al. Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients. AIDS 2004;18:181-7
23. Gilks C, Vitoria M. World Health Organization. Dept. of HIV/AIDS. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 rev. ed. World Health Organization; Geneva: 2006
24. McComsey GA, Lo Re V III, ORiordan M, et al. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis 2008;46:1290-6
25. Yuen GJ, Morris DM, Mydlow PK, et al. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J Clin Pharmacol 1995;35:1174-80
26. Epivir (package insert). Research Traingle Park, NC:GlaxoSmithKline;2011. Available from: http://usgskcom/ products/assets/us-epivirpdf
27. Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998;178:1327-33
28. Retrovir (package insert). Research Traingle Park, NC: GlaxoSmithKline;2011. Available from: http://usgskcom/products/ assets/us-retrovirpdf.
29. Johnson MA, Moore KH, Yuen GJ, et al. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999;36:41-66
30. Moore KH, Barrett JE, Shaw S, et al. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS 1999;13:2239-50
31. Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet 2008;47:351-71
32. Chittick GE, Gillotin C, McDowell JA, et al. Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy 1999;19:932-42
33. Ziagen (package insert). Research Traingle Park, NC: GlaxoSmithKline; 2009. Available from: http://usgskcom/products/ assets/us-ziagenpdf.
34. Best BM, Mirochnick M, Capparelli EV, et al. Impact of pregnancy on abacavir pharmacokinetics. AIDS 2006;20:553-60
35. Moyle G, Boffito M, Fletcher C, et al. Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2009;53:1532-8
36. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003;16:569-96
37. Viread (package insert). Foster City, CA: Gilead Sciences, Inc;2010. Available from: http://wwwgileadcom/pdf/ viread-pipdf
38. Anthonypillai C, Gibbs J, Thomas S. The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses. Cerebrospinal Fluid Res 2006;3:1
39. Van Rompay KKA, Marthas ML, Lifson JD, et al. Administration of 9-[2-(Phosphonomethoxy)propyl] adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res Hum Retroviruses 1998;14:761-73
40. Back DJ, Burger DM, Flexner CW, Gerber JG. The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing. J Acquir Immune Defic Syndr 2005;39:S1-S23
41. Emtriva (package insert). Gilead Sciences, Inc;2008. Available from: http:// wwwgileadcom/pdf/emtriva-pipdf
42. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:185-91
43. Gao Q, Gu Z, Parniak MA, et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′- dideoxyinosine and 2prime;,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′- thiacytidine. Antimicrob Agents Chemother 1993;37:1390-2
44. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993;90:5653-6
45. Staszewski S, Loveday C, Picazo JJ, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA 1996;276:111-17
46. Soudeyns H, Yao XI, Gao Q, et al. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′- deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 1991;35:1386-90
47. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA 1996;276:118-25
48. Katzenstein DA, Hughes M, Albrecht M, et al. Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group. AIDS Res Hum Retroviruses 2000;16:1031-7
49. Staszewski S, Hill AM, Bartlett J, et al. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. AIDS 1997;11:477-83
50. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2293-303
51. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-15
52. Ssali F, Stohr W, Munderi P, et al. Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther 2006;11:741-9
53. Agarwal D, Chakravarty J, Chaube L, et al. High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. Indian J Med Res 2010;132:386-9
54. Fisher M, Moyle GJ, Shahmanesh M, et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr 2009;51:562-8
55. Lafaurie M, Collin F, Bentata M, et al. Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial. J Antimicrob Chemother 2008;62:1122-9
56. Arasteh K, Weitner L, Fenske S, et al. Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT). Eur J Med Res 2009;14:195-9
57. Hurwitz SJ, Asif G, Kivel NM, Schinazi RF. Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model. Antimicrob Agents Chemother 2008;52:4241-50
58. World Health Organization. Dept. of HIV/AIDS, WHO Integrated Management of Adolescent and Adult Illness Project, WHO Integrated Management of Childhood Illness Project. Chronic HIV care with ARV therapy and prevention : Integrated Management of Adolescent and Adult Illness, Integrated Management of Childhood Illness interim guidelines for health workers at health centre or district hospital outpatient clinic. World Health Organization; Geneva: 2007
59. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; January 10, 2011; 1-166 Available at http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf [Last accessed August 10,2011]
60. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292:191-201
61. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF. Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV. N Engl J Med 2006;354:251-60
62. Molina J-M, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ ritonavir versus twice-daily lopinavir/ ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372:646-55
63. Walmsley S, Avihingsanon A, Slim J, et al. Gemini: a noninferiority study of Saquinavir/Ritonavir versus Lopinavir/ Ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr 2009;50:367-74
64. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr 2006;43:535-40
65. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008;47:74-8
66. Turner D, Shahar E, Katchman E, et al. Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel. J Med Virol 2009;81:1509-12
67. Hawkins CA, Chaplin B, Idoko J, et al. Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. J Acquir Immune Defic Syndr 2009;52:228-34
68. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002;16:1257-63
69. Squires K, Pozniak AL, Pierone G Jr, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003;139:313-20
70. Moyle GJ, DeJesus E, Cahn P, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr 2005;38:417-25
71. Sax PE, Tierney C, Collier AC, et al. Abacavir-Lamivudine versus Tenofovir-Emtricitabine for Initial HIV-1 Therapy. N Engl J Med 2009;361:2230-40
72. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/ emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009;23:1547-56
73. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr 2004;37:1489-95
74. Moreno S, Domingo P, Palacios R, et al. Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicenter study. J Acquir Immune Defic Syndr 2006;42:385-7
75. Horberg M, Tang B, Towner W, et al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr 2010;53:62-9
76. Poizot-Martin I, Solas C, Allemand J, et al. Renal Impairment in Patients Receiving a TDF-based cART Regimen: Impact of TDF Concentration? CROI; Boston: 2010
77. Rodriguez-Novoa S, Labarga P, DAvolio A, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS 2010;24:1064-6
78. Rodriguez-Novoa S, Alvarez E, Labarga P, Soriano V. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010;9:545-59
79. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010;51:963-72
80. Grigsby IF, Pham L, Mansky LM, et al. Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochem Biophys Res Commun 2010;394:48-53
81. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202. J Infect Dis 2011;203:1791-801
82. Cassetti I, Madruga JV, Suleiman JM, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 2007;8:164-72
83. Bedimo R, Zhang S, Drechsler H, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents [MOAB0101]. In: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Rome; 2011
84. Albrecht H. Abacavir/3TC vs. tenofovir/ FTC: interim results from ACTG 5202. AIDS Clin Care 2008;20:28
85. Albrecht H. Report from the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. HLA B-5701 and abacavir hypersensitivity. AIDS Clin Care 2007;19:81-2
86. Dvali N, Chkhartishvili N, Sharvadze L, et al. HLA-B*5701 genetic screening prior to abacavir prescription in Georgia. Georgian Med News 2010;16-20
87. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:727-32
88. Cutrell AG, Hernandez JE, Fleming JW, et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother 2004;38:2171-2
89. Orkin C, Sadiq ST, Rice L, Jackson F; on behalf of the UKEPIt. Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects. HIV Med 2010;11:187-92
90. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371:1417-26
91. Lundgren JD, Babiker A, El-Sadr W, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis 2008;197:1145-55
92. Lang S, Mary-Krause M, Cotte L, et al. Impact of specific NRTI and PI exposure on the risk of myocardial infarction: a Case-Control Study Nested within FHDH ANRS CO4. CROI; Montreal, Canada: 2009
93. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009;51:20-8
94. Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ ALLRT. Clin Infect Dis 2011;52:929-40
95. Van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-63
96. Spaulding A, Rutherford GW, Siegfried N. Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naive individuals. Cochrane Database Syst Rev 2010;CD008651
97. Domingo P, Cabeza MC, Pruvost A, et al. Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy. Antimicrob Agents Chemother 2011;55:1428-35
98. Makinson A, Moing VL, Kouanfack C, et al. Safety of stavudine in the treatment of HIV infection with a special focus on resource-limited settings. Expert Opin Drug Saf 2008;7:283-93
99. Gerschenson M, Kim C, Berzins B, et al. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J Antimicrob Chemother 2009;63:1244-50
100. Walensky RP, Wood R, Ciaranello AL, et al. Scaling up the 2010 World Health Organization HIV treatment guidelines in resource-limited settings: a model-based analysis. PLoS Med 2010;7:e1000382
101. Berenguer J, Gonzalez J, Ribera E, et al. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. Clin Infect Dis 2008;47:1083-92
102. Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA 2004;292:180-9
103. Campbell T, Smeaton L, Grutolla VD, et al. PEARLS (ACTG A5175): a multinational study of didanosine-EC, emtricitabine and atazanavir vs. co-formulated zidovudine/lamivudine and efavirenz for initial treatment of HIV-1 infection. In: 17th International AIDS Conference; Mexico City, Mexico; 2008
104. Palacios R, Rivero A, Santos I, et al. Rapid improvement in fasting lipids and hepatic toxicity after switching from didanosine/lamivudine to tenofovir/ emtricitabine in patients with toxicity attributable to didanosine. HIV Clin Trials 2010;11:118-20
105. Vispo E, Morello J, Rodriguez-Novoa S, Soriano V. Noncirrhotic portal hypertension in HIV infection. Curr Opin Infect Dis 2011;24:12-18
106. Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009;49:626-35
107. Setzer B, Schlesier M, Thomas AK, Walker UA. Mitochondrial toxicity of nucleoside analogues in primary human lymphocytes. Antivir Ther 2005;10:327-34
108. Maitland D, Moyle G, Hand J, et al. Early virologic failure in HIV-1 infected subjects on didanosine/ tenofovir/efavirenz: 12-week results from a randomized trial. AIDS 2005;19:1183-8
109. Leon A, Martinez E, Mallolas J, et al. Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine. AIDS 2005;19:213-15
110. Martinez E, Milinkovic A, de Lazzari E, et al. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Lancet 2004;364:65-7
111. Gulick R, Ribaudo H, Shikuma C, et al. ACTG 5095: a comparative study OF 3 protease inhibitor-sparing antiretroviral regimens for the initial treatment of HIV infection. Antivir Ther 2003;8(Suppl 1):abstract 41
112. Munderi P, Walker AS, Kityo C, et al. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/ lamivudine in HIV-infected Ugandan adults with low CD4 cell counts. HIV Med 2010;11:334-44
113. Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005;192:1921-30
114. Landman R, Descamps D, Peytavin G, et al. Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study. HIV Clin Trials 2005;6:291-301
115. Ferrer E, Gatell JM, Sanchez P, et al. Zidovudine/ Lamivudine/Abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective One-Arm Pilot Study. AIDS Res Hum Retroviruses 2008;24:931-4
116. Rodriguez AE, Dejesus E, Williams V, et al. Efficacy and safety of Abacavir/Lamivudine/Zidovudine plus tenofovir in HBV/HIV-1 coinfected adults: 48-week Data. Open AIDS J 2010;4:167-70
117. Puls RL, Srasuebkul P, Petoumenos K, et al. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis 2010;51:855-64
118. van de Vijver DA, Wensing AM, Asjo B, et al. HIV-1 drug-resistance patterns among patients on failing treatment in a large number of European countries. Acta Dermatovenerol Alp Panonica Adriat 2010;19:3-9
119. Campbell-Yesufu OT, Gandhi RT. Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis 2011;52:780-7
120. Ntemgwa ML, Toni TdA, Brenner BG, et al. Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother 2009;53:3611-19
121. Desbois D, Roquebert B, Peytavin G, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008;52:1545-8
122. Arien KK, Vanham G. First real success for anti-HIV gel: a new start for HIV microbicides? Future Microbiol 2010;5:1621-3
123. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-74
124. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-99
125. Baeten J, Celum C. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study [MOAX0106]. In: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Rome, Italy; 2011
126. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-Sparing Regimens for Initial Treatment of HIV-1 Infection. N Engl J Med 2008;358:2095-106
127. Reynes J, Lawal A, Pulido A, et al. Lopinavir/ritonavir combined with raltegravir demonstrated similar antiviral efficacy and safety as lopinavir/ritonavir combined with tenofovir disoproxil fumarate/emtricitabine in treatment-naive HIV-1 infected subjects [MOAB0101]. In: XVIII International AIDS Conference; Vienna, Austria; 2010
128. Taiwo B, Zheng L, Gallien S, et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS 2011;25:2113-22
129. Arribas JR, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010;24:223-30
130. Katlama C, Valantin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010;24:2365-74
131. Markowitz M, Zolopa A, Ruane P, et al. GS-7340 Demonstrates greater declines in HIV-1 RNA than tenofovir disoproxilfumarate during 14 days of monotherapyin HIV-1 infected subjects. In: 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011); Boston; 2011
132. Cahn P, Wainberg MA. Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine. J Antimicrob Chemother 2010;65:213-17
133. Murphy RL, Kivel NM, Zala C, et al. Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals. Antivir Ther 2010;15:185-92